Good evening. This snapshot of stories and roundup is recommended just for you, based on your interests and reading history. | | |  What to know The article discusses the complexities of PSA testing for prostate cancer, highlighting its benefits and drawbacks. Studies show PSA tests can reduce mortality but also lead to overdiagnosis and unnecessary treatments. The U.S. Preventive Services Task Force recommends individualized decisions for men aged 55-69 and advises against screening for those over 70. Summary is AI-generated, newsroom-reviewed. | | | | | How was today's newsletter? | | | | | | | | |
Have a question? Ask the Post AI to learn more 
